Ardent Health, Inc. owns and operates a network of hospitals and clinics that provides healthcare services in the United States. The company offers general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women's services, neurology, urology, and emergency services within inpatient and ambulatory care settings. It also operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers, urgent care centers, free-standing emergency departments, and diagnostic imaging centers. The company operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. Ardent Health, Inc. was formerly known as Ardent Health Partners, Inc. and changed its name to Ardent Health, Inc. in June 2025. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health, Inc. is a subsidiary of EGI-AM Investments, L.L.C.…
Eight Ardent Health Facilities Earn ‘A’ Hospital Safety Grades from The Leapfrog Group for Fall 2026 Grading Period
Ardent Health (NYSE: ARDT) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 19,500 employees.
The shares were at 15.08 USD on 20 November 2026, up 82.1% over 52 weeks. Its 52-week range is 7.710 USD to 18.57 USD: the price is 18.8% below the high and 95.6% above the low.
At a market capitalisation of 2.10B USD, it trades at 14.6 times trailing earnings and 10.9 times forward earnings. The median trailing P/E of its 18 largest Medical Care Facilities peers is 23.8, a discount of 39% for ARDT.
Ardent Health reports return on equity of 10.5%, an operating margin of 5.1% and revenue up 3.1% year over year.
Its debt exceeds its cash by 1.50B USD, a debt-to-equity ratio of 1.80. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 12 analysts cover the stock, with an average rating of Buy; their mean price target of 17.38 USD is 15.2% above the current price. The next earnings report is expected on 3 March 2027.